A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Inclusion criteria

• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART)
• If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks
• If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load
• Has adequate organ function

Exclusion criteria

• If prior anticancer therapy is allowed, participants are excluded if they received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before allocation
• Has received prior locoregional therapy within 2 weeks of start of study intervention, or has ongoing locoregional treatment-related toxicities
• Is currently receiving any anticoagulants
• Was discontinued from prior immunotherapy due to a Grade ≥3 immune-related adverse event (irAE)
• Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
• Has known additional malignancy that is progressing or has required active treatment within the past 2 years
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Has active autoimmune disease that has required systemic treatment in the past 2 years
• Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments
• Active or ongoing stomatitis and/or mucositis of any grade
• HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
• Has history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
• Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
• Has history of stem cell/solid organ transplant
• Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications
• Has clinically significant hemoptysis, hematemesis, or tumor bleeding within 4 weeks before the first dose of study intervention
• Has any clinically significant or life-threatening bleeding event that occurred within 3 months prior to the first dose of the study intervention
• Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
• Has any history of myocarditis or cardiomyopathy
• Has a current or history of severe cardiovascular and cerebrovascular diseases